Bleeding is a major adverse event reported in some clinical trials caused by angiogenesis inhibitors disrupting the tumor vasculature by inhibiting VEGF signaling, leading to thrombosis or bleeding [24, 25]. This evidence concerns the gene VEGFA and neoplasm.